Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation-Reference-Cited by-同舟云学术

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

Published:2015-10-22 Issue:17 Volume:126 Page:2062-2069
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Schmid Christoph¹,Labopin Myriam²,Socié Gerard³,Daguindau Etienne⁴,Volin Liisa⁵,Huynh Anne⁶,Bourhis Jean Henri⁷,Milpied Noel⁸,Cornelissen Jan⁹,Chevallier Patrice¹⁰,Maertens Johan¹¹,Jindra Pavel¹²,Blaise Didier¹³,Lenhoff Stig¹⁴,Ifrah Norbert¹⁵,Baron Frédéric¹⁶,Ciceri Fabio¹⁷,Gorin Claude¹⁸,Savani Bipin¹⁹,Giebel Sebastian²⁰,Polge Emmanuelle²¹,Esteve Jordi²²,Nagler Arnon²³,Mohty Mohamad²⁴

Affiliation:

1. Klinikum Augsburg, Department of Hematology and Oncology, University of Munich, Augsburg, Germany;

2. Faculté de Médicine Saint-Antoine and European Group of Blood and Bone Marrow Transplantation (EBMT) Data Office, Paris, France;

3. Hopital St. Louis, Department of Hematology–Blood and Marrow Transplantation (BMT), Paris, France;

4. Centre Hospitalier Regional Universitaire (CHRU) Besançon, Service d'Hématologie, Besançon, France;

5. Helsinki University Hospital, Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland;

6. Institut Universitaire du Cancer de Toulouse Oncopole, Hematology Department, Toulouse, France;

7. Gustave Roussy, Institut de Cancérologie-BMT Service, Division of Hematology-Department of Medical Oncology, Villejuif, France;

8. Centre Hospitalier Universitaire (CHU) Bordeaux-Hôpital Haut-Leveque, Pessac, France;

9. Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands;

10. CHU Nantes-Department D‘Hematologie, Nantes, France;

11. University Hospital Gasthuisberg, Department of Hematology, Leuven, Belgium;

12. Charles University Hospital-Department of Hematology/Oncology, Pilsen, Czech Republic;

13. Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille-Institut Paoli Calmettes, Marseille, France;

14. University Hospital, Lund, Sweden;

15. CHRU, Service des Maladies du Sang, Angers, France;

16. Department of Medicine, Division of Hematology, University of Liège, Belgium;

17. Department of Hematology, Ospedale San Raffaele, Università degli Studi, Milano, Italy;

18. Faculté de Médicine Saint-Antoine, Paris, France;

19. Long-Term Transplant Clinic, Vanderbilt University Medical Center, Nashville, TN;

20. Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland;

21. Faculté de Médicine Saint-Antoine and EBMT data office, Paris, France;

22. Department of Hematology, Hospital Clinic, Institut D'investigacions Biomediques August Pi y Sunyer, Barcelona, Spain;

23. Chaim Sheba Medical Center, Tel-Hashomer, Israel; and

24. Faculté de Médicine Saint-Antoine and EBMT Data Office, Paris, France

Abstract

Key Points In AML with normal cytogenetics, age, response to induction, and FLT3-ITD allow for an estimate of outcome after allogeneic HSCT in CR1. Neither variation of classical transplant techniques nor development of chronic GVHD outweighs the negative impact of FLT3-ITD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/17/2062/1389350/2062.pdf

Reference41 articles.

1. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.;Koreth;JAMA,2009

2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.;Döhner;Blood,2010

3. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.;Cornelissen;Nat Rev Clin Oncol,2012

4. Clinical relevance of mutations and gene-expression changes in adult AML with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?;Mrozek;Blood,2007

5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.;Schlenk;N Engl J Med,2008

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia;2023-10-30

2. Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia;BMC Cancer;2023-10-24

3. Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party;Clinical Cancer Research;2023-08-21

4. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study;Transplantation and Cellular Therapy;2023-07

5. Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia;Hematology;2023-06-05